Comparing EPA and DHA absorption from fortified soymilk and capsules
Bioavailability and Pharmacodynamics of Eicosapentaenoic Acid and Docosahexaenoic Acid in Soymilk and Commercial Supplements
This study is testing whether drinking fortified soymilk or taking algae oil capsules helps people absorb omega-3 fatty acids better over six weeks.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT05802797 on ClinicalTrials.gov |
What this trial studies
This study aims to compare the absorption of omega-3 fatty acids EPA and DHA from algae oil fortified soymilk against a commercial algae oil capsule. Participants will consume either the soymilk or capsules daily for six weeks, with blood samples taken at four intervals to measure the accumulation of these fatty acids in blood lipid pools. The research addresses dietary restrictions and sustainability issues associated with traditional fish oil consumption, providing a potential alternative for increasing omega-3 intake among consumers. A food frequency questionnaire will also be completed by participants to gather dietary information.
Who should consider this trial
Good fit: Ideal candidates are healthy adults with a body mass index between 18 and 30 kg/m2.
Not a fit: Patients who are pregnant, nursing, or have certain medical conditions such as diabetes or high cholesterol may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a sustainable and accessible source of omega-3 fatty acids for individuals who cannot consume fish oil.
How similar studies have performed: Other studies have shown promising results with similar approaches using algae oil for omega-3 supplementation, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Body mass index between 18 and 30 kg/m2 Exclusion Criteria: * Being pregnant or nursing * Having anemia or a condition that influences the ability to donate blood safely * Allergies to the beverage or pill ingredients * Diabetes * High triglycerides or cholesterol * Coagulation disorder * Anticoagulation therapy or any drug that affects blood clotting. * Taking prescribed dietary omega-3 fatty acid medications including fish oil or algae oil within the last 3 months * Taking non-prescribed dietary omega-3 fatty acid supplements within the last 3 months and not willing to discontinue taking them for the study period * Taking lipid lowering medications such as statins * Sensory impairments which affect ability to taste, smell, or see food products
Where this trial is running
Columbus, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Yael Vodovotz, PhD — Ohio State University
- Study coordinator: Yael Vodovotz, PhD
- Email: vodovotz.1@osu.edu
- Phone: 614-247-7696
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.